Ira Jacobson
Overview
Explore the profile of Ira Jacobson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1527
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Das T, Ho K, Udaikumar J, Chen B, Delau O, Shaukat A, et al.
Hepatol Res
. 2024 Feb;
54(9):807-816.
PMID: 38419394
Aim: Primary sclerosing cholangitis (PSC) increases the risk of colorectal cancer (CRC) in inflammatory bowel disease (IBD) patients; however, there is a paucity of literature to suggest PSC alone as...
2.
Ho K, Garcia-Aguilar J, Nagao S, Jacobson I
ACG Case Rep J
. 2023 Oct;
10(10):e01151.
PMID: 37829168
No abstract available.
3.
Younossi Z, Corey K, Alkhouri N, Noureddin M, Jacobson I, Lam B, et al.
Aliment Pharmacol Ther
. 2020 Jun;
52(3):513-526.
PMID: 32598051
Background: Primary care practitioners (PCPs) and diabetologists are at the frontline of potentially encountering patients with NASH. Identification of those at high risk for adverse outcomes is important. Aim: To...
4.
Reyentovich A, Gidea C, Smith D, Lonze B, Kon Z, Fargnoli A, et al.
Clin Transplant
. 2020 May;
34(9):e13989.
PMID: 32441413
Background: The use of direct-acting antivirals (DAA) has expanded transplantation from hepatitis C viremic donors (HCV-VIR). Our team has conducted an open-label, prospective trial to assess outcomes transplanting HCV viremic...
5.
Whitsett M, Feldman D, Jacobson I
Liver Transpl
. 2020 Feb;
26(5):709-717.
PMID: 32061053
Hepatitis E virus (HEV), of the family Herpesviridae, is a virus that infects nearly 20 million people per year throughout the world. HEV is most commonly transmitted via the fecal-oral...
6.
Younossi Z, Stepanova M, Lawitz E, Reddy K, Wong V, Mangia A, et al.
Am J Gastroenterol
. 2019 Aug;
114(10):1636-1641.
PMID: 31464743
Introduction: Although there is substantial evidence suggesting poor health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC), similar data in nonalcoholic steatohepatitis (NASH) have not been fully...
7.
Younossi Z, Stepanova M, Jacobson I, Muir A, Pol S, Zeuzem S, et al.
Clin Infect Dis
. 2019 Apr;
70(4):628-632.
PMID: 30949674
Background: The causative relationship between the clearance of infections and long-term, health-related quality-of-life (HRQL) improvements in patients with hepatitis C virus (HCV) has been generally accepted. The aim of this...
8.
Adinolfi L, Jacobson I, Bondin M, Cacoub P
Antivir Ther
. 2018 Nov;
23(Suppl 2):11-21.
PMID: 30451154
Type 2 diabetes mellitus (T2DM) has been identified as an extrahepatic manifestation of chronic HCV infection. Conversely, in the context of chronic HCV infection, T2DM can accelerate the course of...
9.
Serfaty L, Jacobson I, Rockstroh J, Altice F, Hwang P, Barr E, et al.
J Viral Hepat
. 2018 Nov;
26(3):329-336.
PMID: 30412325
European treatment guidelines for hepatitis C virus (HCV) infection recommend that people with genotype (GT) 1a infection and baseline viral load ≤800 000 IU/mL receive elbasvir/grazoprevir (EBR/GZR) for 12 weeks,...
10.
Grebely J, Feld J, Wyles D, Sulkowski M, Ni L, Llewellyn J, et al.
Open Forum Infect Dis
. 2018 Feb;
5(2):ofy001.
PMID: 29450210
Background: Hepatitis C virus (HCV) direct-acting antiviral therapy is effective among people receiving opioid substitution therapy (OST), but studies are limited by small numbers of nongenotype 1 (GT1) patients. The...